NEW
YORK, Aug. 4, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, today announced
that it will host its earnings call on Thursday, August 11, 2022, at 4:30 p.m. EDT to discuss its financial results
for the quarter ended June 30, 2022
and provide a business update.
Individuals may participate via telephone by dialing (800)
920-2776 (domestic) or (416) 981-9033 (international) and using
conference ID 22019820. The webcast can be accessed live here or on
MindMed's Investor Resources webpage. The webcast will be archived
on the company's website for at least 30 days after the conference
call.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, with a particular
focus on psychiatry, addiction, pain and neurology. Our mission is
to be the global leader in the development and delivery of
treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-to-host-earnings-call-to-discuss-second-quarter-2022-financial-results-and-provide-business-update-301599817.html
SOURCE Mind Medicine (MindMed) Inc.